Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
M	O
Service:	O
MEDICINE	O
Allergies:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending:	O
___.	O
Chief	O
Complaint:	O
left	O
leg	O
weakness	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
None	O
History	O
of	O
Present	O
Illness:	O
Mr.	O
___	O
is	O
a	O
___	O
yo	O
male	O
with	O
PMHx	O
HTN,	O
T2DM,	O
CKD	O
and	O
prostate	O
cancer	O
currently	O
being	O
treated	O
with	O
chemotherapy	O
who	O
presents	O
from	O
___	O
facility	O
with	O
low-grade	O
fevers	O
and	O
left	O
leg	O
numbness/tingling.	O
Pt	O
recently	O
started	O
on	O
a	O
chemotherapy	O
regimen	O
3	O
months	O
for	O
prostate	O
cancer.	O
Last	O
treatment	O
was	O
8	O
days	O
ago,	O
total	O
3	O
sessions.	O
Pt	O
unsure	O
of	O
the	O
name	O
of	O
the	O
___.	O
Has	O
been	O
experiencing	O
fevers	O
and	O
generalized	O
weakness.	O
Also	O
with	O
numbness	O
and	O
tingling	O
down	O
his	O
left	O
leg	O
for	O
the	O
past	O
___	O
weeks.	O
Pt	O
is	O
currently	O
in	O
a	O
___	O
facility	O
where	O
he	O
was	O
seen	O
by	O
a	O
physician	O
who	O
sent	O
him	O
to	O
___.	O
At	O
___,	O
there	O
were	O
concerns	O
for	O
hyperkalemia,	O
which	O
was	O
treated	O
with	O
calcium,	O
insulin/dextrose	O
and	O
albuterol.	O
In	O
the	O
ED:	O
-	O
Initial	O
vital	O
signs:	O
T	O
97.7,	O
HR	O
95,	O
BP	O
151/91,	O
RR	O
18,	O
O2	O
98%	O
RA	O
FSBG	O
60	O
-	O
Exam	O
notable	O
for:	O
___	O
strength	O
in	O
bl	O
UE,	O
weakness	O
with	O
left	O
foot	O
dorsiflexion,	O
sensation	O
to	O
light	O
touch	O
intact	O
throughout,	O
normal	O
rectal	O
tone	O
-	O
Labs	O
were	O
notable	O
for:	O
WBC	O
3.1	O
-->	O
2.4,	O
ANC	O
1.44	O
-->	O
1.03,	O
Hgb	O
7.9	O
-->	O
8.3,	O
Plt	O
338,	O
Na	O
135	O
-->	O
134,	O
K	O
4.1	O
-->	O
4.4,	O
Cr	O
0.9,	O
Ca	O
8.9,	O
Mg	O
1.7,	O
Phos	O
1.9,	O
LFTs	O
wnl,	O
Tbili	O
0.3,	O
Lactate	O
1.6	O
-	O
Studies	O
performed	O
include:	O
--	O
UA:	O
few	O
bacteria,	O
neg	O
leuks,	O
neg	O
nitrite,	O
tr	O
blood,	O
30	O
protein,	O
300	O
glucose	O
--	O
CXR:	O
Hyperdensity	O
overlying	O
the	O
vertebrae	O
of	O
the	O
lower	O
thoracic	O
spine	O
may	O
represent	O
metastatic	O
disease.	O
Superimposed	O
pneumonia	B-Lower_respiratory_tract_infection
or	O
nodule	O
cannot	O
be	O
excluded.	O
--	O
MRI	O
C/T/L	O
Spine	O
-	O
extensive	O
osseous	O
metastatic	O
disease,	O
C5	O
signal	O
abnormality	O
with	O
cord	O
edema	O
C3-C5	O
without	O
enhancement,	O
spinal	O
canal	O
narrowing/stenosis	O
in	O
the	O
lumbar	O
spine,	O
retroperitoneal	O
LAD	O
--	O
L-spine	O
Flex/Ext	O
-	O
sclerotic	O
lesions	O
c/f	O
mets,	O
anterolisthesis	O
of	O
L3/L4	O
without	O
change	O
in	O
alignment	O
with	O
flexion/extension.	O
-	O
Patient	O
was	O
given:	O
___	O
11:52	O
PO	O
PredniSONE	O
10	O
mg	O
___	O
12:39	O
PO	O
Furosemide	O
20	O
mg	O
___	O
12:39	O
PO	O
Diltiazem	O
Extended-Release	O
360	O
mg	O
___	O
12:39	O
PO	O
Pantoprazole	O
40	O
mg	O
___	O
12:39	O
PO	O
Isosorbide	O
Dinitrate	O
20	O
mg	O
___	O
12:39	O
PO	O
Naproxen	O
500	O
mg	O
___	O
16:20	O
IH	O
Albuterol	O
Inhaler	O
2	O
PUFF	O
___	O
16:20	O
PO	O
Calcium	O
Carbonate	O
500	O
mg	O
-	O
Consults:	O
Spine	O
-	O
no	O
emergent	O
intervention,	O
would	O
likely	O
benefit	O
from	O
lumbar	O
spine	O
decompression	O
as	O
an	O
outpatient	O
Vitals	O
on	O
transfer:	O
T	O
99,	O
HR	O
94,	O
BP	O
141/78,	O
RR	O
16,	O
O2	O
92%	O
RA	O
Upon	O
arrival	O
to	O
the	O
floor,	O
pt	O
endorsing	O
above	O
history.	O
States	O
he	O
has	O
had	O
left	O
lateral	O
leg	O
numbness/tingling	O
for	O
the	O
past	O
few	O
weeks.	O
Felt	O
generalized	O
weakness	O
last	O
week	O
several	O
days	O
after	O
his	O
___	O
session,	O
as	O
well	O
as	O
fever	O
up	O
to	O
104	O
last	O
week.	O
Endorses	O
subjective	O
fevers	O
and	O
night	O
sweats.	O
Had	O
nausea	O
after	O
___	O
as	O
well	O
as	O
diarrhea,	O
now	O
resolved.	O
Has	O
chronic	O
dry	O
cough	O
related	O
to	O
post-nasal	O
drip.	O
Otherwise	O
denies	O
chills,	O
ha,	O
lh/dizziness,	O
sob,	O
palp,	O
abd	O
pain,	O
vomiting,	O
constipation,	B-Constipation
BRBPR	B-Lower_gastrointestinal_haemorrhage
or	O
melena.	B-Upper_gastrointestinal_haemorrhage
Endorses	O
low	O
back	O
pain	O
in	O
band-like	O
distribution.	O
States	O
he	O
previously	O
had	O
decreased	O
sensation	O
in	O
groin	O
area	O
related	O
to	O
a	O
urinary	O
catheter	O
he	O
had	O
?	O
now	O
improved.	O
Had	O
urinary	B-Urinary_incontinence
incontinence	B-Urinary_incontinence
at	O
that	O
time	O
d/t	O
the	O
decreased	O
sensation,	O
none	O
recently.	O
Had	O
episode	O
of	O
rectal	B-Faecal_incontinence
incontinence	B-Faecal_incontinence
last	O
week	O
related	O
to	O
diarrhea,	O
otherwise	O
has	O
regular	O
BMs	O
without	O
incontinence.	B-Urinary_incontinence
Past	O
Medical	O
History:	O
Prostate	O
Cancer	O
T2DM	O
HTN	O
Asthma	O
GERD	O
___	O
___	O
History:	O
___	O
Family	O
History:	O
Mom	O
-	O
leukemia	O
Unable	O
to	O
provide	O
further	O
family	O
history	O
Physical	O
Exam:	O
ADMISSION	O
PHYSICAL	O
EXAM:	O
======================	O
VITALS:	O
T	O
98.4,	O
HR	O
89,	O
BP	O
148/78,	O
RR	O
18,	O
O2	O
95%	O
RA	O
GENERAL:	O
Alert	O
and	O
interactive.	O
In	O
no	O
acute	O
distress.	O
HEENT:	O
NCAT.	O
PERRL,	O
EOMI	O
however	O
limited	O
abduction	O
bl.	O
Sclera	O
anicteric	O
and	O
without	O
injection.	O
MMM.	O
Thyroid	O
is	O
normal	O
in	O
size	O
and	O
texture,	O
no	O
nodules.	O
CARDIAC:	O
Regular	O
rhythm,	O
normal	O
rate.	O
Audible	O
S1	O
and	O
S2.	O
No	O
murmurs/rubs/gallops.	O
No	O
JVD.	O
RESP:	O
Crackles	O
in	O
bl	O
bases,	O
otherwise	O
clear	O
to	O
auscultation	O
bilaterally.	O
No	O
wheezes	O
or	O
rhonchi.	O
No	O
increased	O
work	O
of	O
breathing	O
on	O
RA.	O
ABDOMEN:	O
Normal	O
bowels	O
sounds,	O
non	O
distended,	O
non-tender	O
to	O
deep	O
palpation	O
in	O
all	O
four	O
quadrants.	O
MSK:	O
No	O
spinous	O
process	O
tenderness.	O
No	O
CVA	O
tenderness.	O
EXT:	O
No	O
clubbing,	O
cyanosis,	O
or	O
edema.	O
Pulses	O
DP/Radial	O
2+	O
bilaterally.	O
SKIN:	O
Warm.	O
No	O
rash.	O
NEUROLOGIC:	O
CN2-12	O
intact.	O
___	O
strength	O
throughout	O
other	O
than	O
left	O
big	O
toe	O
dorsiflexion.	O
Decreased	O
sensation	O
of	O
lateral	O
plantar	O
surface	O
of	O
left	O
foot,	O
otherwise	O
wnl	O
sensation	O
to	O
light	O
touch	O
bl,	O
including	O
saddle	O
region.	O
AOx3.	B-Delirium
PSYCH:	O
appropriate	O
mood	O
and	O
affect	O
DISCHARGE	O
PHYSICAL	O
EXAM:	O
========================	O
VS:	O
Temp:	O
98.8	O
(Tm	O
98.8),	O
BP:	O
121/75	O
(121-134/73-77),	O
HR:	O
88	O
(84-96),	O
RR:	O
18	O
(___),	O
O2	O
sat:	O
94%	O
(94-96),	O
O2	O
delivery:	O
RA	O
GENERAL:	O
Alert	O
and	O
interactive.	O
sitting	O
up	O
and	O
eating	O
breakfast	O
CARDIAC:	O
Normal	O
S1/S2	O
with	O
RRR,	O
no	O
MRG	O
RESP:	O
lungs	O
CTAB	O
without	O
wheezes	O
or	O
rhonchi.	O
No	O
increased	O
work	O
of	O
breathing	O
on	O
RA.	O
ABDOMEN:	O
Normal	O
bowels	O
sounds,	O
non	O
distended,	O
non-tender	O
to	O
deep	O
palpation	O
in	O
all	O
four	O
quadrants.	O
EXT:	O
No	O
clubbing,	O
cyanosis,	O
or	O
edema.	O
Pulses	O
DP/Radial	O
2+	O
bilaterally.	O
SKIN:	O
Warm.	O
No	O
rash.	O
NEUROLOGIC:	O
A&Ox3,	B-Delirium
face	O
symmetric,	O
speech	O
fluent.	O
___	O
strength	O
in	O
b/l	O
UE	O
and	O
proximal	O
___.	O
___	O
with	O
left	O
foot	O
dorsiflexion,	O
___	O
left	O
great	O
toe	O
dorsiflexion.	O
PSYCH:	O
appropriate	O
mood	O
and	O
affect	O
Pertinent	O
Results:	O
ADMISSION	O
LABS:	O
==================	O
___	O
06:25PM	O
BLOOD	O
WBC-3.1*	O
RBC-3.26*	O
Hgb-7.9*	O
Hct-27.0*	O
MCV-83	O
MCH-24.2*	O
MCHC-29.3*	O
RDW-20.3*	O
RDWSD-60.7*	O
Plt	O
___	O
___	O
06:25PM	O
BLOOD	O
Neuts-46.5	O
___	O
Monos-8.4	O
Eos-0.0*	O
Baso-0.6	O
Im	O
___	O
AbsNeut-1.44*	O
AbsLymp-1.36	O
AbsMono-0.26	O
AbsEos-0.00*	O
AbsBaso-0.02	O
___	O
06:25PM	O
BLOOD	O
___	O
PTT-32.2	O
___	O
___	O
06:25PM	O
BLOOD	O
Glucose-109*	O
UreaN-12	O
Creat-0.9	O
Na-135	O
K-4.1	O
Cl-100	O
HCO3-22	O
AnGap-13	O
___	O
06:25PM	O
BLOOD	O
ALT-7	O
AST-15	O
AlkPhos-62	O
TotBili-0.3	O
___	O
06:25PM	O
BLOOD	O
Albumin-3.7	O
Calcium-8.9	O
Phos-1.9*	O
Mg-1.7	O
___	O
07:00PM	O
BLOOD	O
Hapto-253*	O
___	O
06:33PM	O
BLOOD	O
Lactate-1.6	O
K-3.8	O
DISCHARGE	O
LABS:	O
==================	O
___	O
07:10AM	O
BLOOD	O
WBC-5.5	O
RBC-3.59*	O
Hgb-8.7*	O
Hct-29.9*	O
MCV-83	O
MCH-24.2*	O
MCHC-29.1*	O
RDW-19.7*	O
RDWSD-58.7*	O
Plt	O
___	O
___	O
06:50AM	O
BLOOD	O
Neuts-27.5*	O
___	O
Monos-23.9*	O
Eos-0.0*	O
Baso-0.3	O
Im	O
___	O
AbsNeut-0.97*	O
AbsLymp-1.63	O
AbsMono-0.84*	O
AbsEos-0.00*	O
AbsBaso-0.01	O
___	O
07:10AM	O
BLOOD	O
Glucose-134*	O
UreaN-21*	O
Creat-1.2	O
Na-133*	O
K-5.2	O
Cl-97	O
HCO3-24	O
AnGap-12	O
___	O
07:10AM	O
BLOOD	O
Calcium-9.4	O
Phos-3.4	O
Mg-2.1	O
MICRO:	O
==================	O
___	O
6:04	O
pm	O
URINE	O
**FINAL	O
REPORT	O
___	O
URINE	O
CULTURE	O
(Final	O
___:	O
MIXED	O
BACTERIAL	O
FLORA	O
(	O
>=	O
3	O
COLONY	O
TYPES),	O
CONSISTENT	O
WITH	O
SKIN	O
AND/OR	O
GENITAL	O
CONTAMINATION.	O
x3	O
ACID	O
FAST	O
SMEAR	O
(Final	O
___:	O
NO	O
ACID	O
FAST	O
BACILLI	O
SEEN	O
ON	O
CONCENTRATED	O
SMEAR.	O
MTB	O
Direct	O
Amplification	O
(Final	O
___:	O
M.	O
TUBERCULOSIS	O
DNA	O
NOT	O
DETECTED	O
BY	O
NAAT:	O
A	O
negative	O
NAAT	O
cannot	O
rule	O
out	O
TB	O
or	O
other	O
mycobacterial	O
infection.	O
.	O
NAAT	O
results	O
will	O
be	O
followed	O
by	O
confirmatory	O
testing	O
with	O
conventional	O
culture	O
and	O
DST	O
methods.	O
This	O
TB	O
NAAT	O
method	O
has	O
not	O
been	O
approved	O
by	O
FDA	O
for	O
clinical	O
diagnostic	O
purposes.	O
However,	O
this	O
laboratory	O
has	O
established	O
assay	O
performance	O
by	O
in-house	O
validation	O
in	O
accordance	O
with	O
CLIA	O
standards.	O
.	O
Test	O
done	O
at	O
___	O
Mycobacteriology	O
Laboratory.	O
Test	O
Result	O
Reference	O
Range/Units	O
QUANTIFERON(R)-TB	O
GOLD	O
PLUS,	O
NEGATIVE	O
NEGATIVE	O
4T,	O
INCUBATED	O
Negative	O
test	O
result.	O
M.	O
tuberculosis	O
complex	O
infection	O
unlikely.	O
IMAGING:	O
==================	O
CXR	O
___:	O
IMPRESSION:	O
Hyperdensity	O
overlying	O
the	O
vertebrae	O
of	O
the	O
lower	O
thoracic	O
spine	O
may	O
represent	O
osseous	O
metastatic	O
disease.	O
Superimposed	O
pulmonary	O
abnormality	O
such	O
as	O
pneumonia	B-Lower_respiratory_tract_infection
or	O
nodule	O
cannot	O
be	O
excluded.	O
MRI	O
Spine	B-Vertebral_compression_fracture
___:	O
IMPRESSION:	O
1.	O
Extensive	O
osseous	O
metastatic	O
disease.	O
No	O
associated	O
pathologic	O
compression	B-Vertebral_compression_fracture
fracture	B-Vertebral_compression_fracture
2.	O
There	O
is	O
an	O
area	O
of	O
T2	O
area	O
of	O
signal	O
abnormality	O
in	O
the	O
dorsal	O
spinal	O
canal	O
at	O
the	O
C5	O
level,	O
without	O
convincing	O
enhancement.	O
It	O
is	O
of	O
uncertain	O
etiology	O
and	O
small	O
metastatic	O
focus	O
is	O
not	O
excluded	O
in	O
the	O
context	O
of	O
the	O
fairly	O
extensive	O
metastases	O
although	O
it	O
does	O
not	O
clearly	O
enhance.	O
Further	O
assessment	O
from	O
high-resolution	O
targeted	O
imaging	O
of	O
the	O
cervical	O
spine	O
may	O
be	O
useful.	O
It	O
does	O
not	O
cause	O
definite	O
compression	O
of	O
the	O
spinal	O
cord,	O
although	O
of	O
note,	O
there	O
is	O
spinal	O
cord	O
edema	O
at	O
C3	O
through	O
C5	O
without	O
enhancement,	O
near	O
the	O
indeterminate	O
focus	O
of	O
signal	O
abnormality.	O
3.	O
Retroperitoneal	O
lymphadenopathy	O
likely	O
reflecting	O
metastatic	O
disease.	O
4.	O
Multilevel	O
degenerative	O
changes	O
throughout	O
the	O
spine	O
most	O
pronounced	O
in	O
the	O
lower	O
lumbar	O
spine	O
with	O
severe	O
neural	O
foraminal	O
narrowing	O
at	O
the	O
L4-L5	O
and	O
L5-S1	O
levels	O
as	O
well	O
as	O
severe	O
spinal	O
canal	O
stenosis	O
at	O
L3-L4	O
and	O
L4-L5.	O
PREVALENCE:	O
Prevalence	O
of	O
lumbar	O
degenerative	O
disk	O
disease	O
in	O
subjects	O
without	O
low	O
back	O
pain:	O
Overall	O
evidence	O
of	O
disk	O
degeneration	O
91%	O
(decreased	O
T2	O
signal,	O
height	O
loss,	O
bulge)	O
T2	O
signal	O
loss	O
83%	O
Disk	O
height	O
loss	O
58%	O
Disk	O
protrusion	O
32%	O
Annular	O
fissure	O
38%	O
Jarvik,	O
et	O
all.	O
Spine	O
___	O
26(10):1158-1166	O
Lumbar	O
spinal	O
stenosis	O
prevalence-	O
present	O
in	O
approximately	O
20%	O
of	O
asymptomatic	O
adults	O
over	O
___	O
years	O
old	O
___,	O
et	O
al,	O
Spine	O
Journal	O
___	O
9	O
(7):___	O
These	O
findings	O
are	O
so	O
common	O
in	O
asymptomatic	O
persons	O
that	O
they	O
must	O
be	O
interpreted	O
with	O
caution	O
and	O
in	O
context	O
of	O
the	O
clinical	O
situation.	O
L	O
SPINE	O
FLEX	O
and	O
EXT:	O
___	O
IMPRESSION:	O
Anterolisthesis	O
of	O
L3	O
on	O
L4	O
without	O
change	O
in	O
alignment	O
between	O
flexion	O
and	O
extension.	O
Degenerative	O
changes.	O
Multifocal	O
sclerotic	O
lesions	O
concerning	O
for	O
metastatic	O
disease.	O
HIP	O
X-RAY	O
___:	O
IMPRESSION:	O
No	O
previous	O
images.	O
There	O
are	O
multiple	O
areas	O
of	O
sclerosis	O
involving	O
the	O
visualized	O
lumbar	O
vertebral	O
bodies	O
as	O
well	O
as	O
several	O
bones	O
of	O
the	O
pelvis,	O
consistent	O
with	O
the	O
clinical	O
diagnosis	O
of	O
metastatic	O
prostate	O
cancer.	O
Substantial	O
hypertrophic	O
spurring	O
and	O
intervertebral	O
disc	O
space	O
narrowing	O
is	O
consistent	O
with	O
degenerative	O
changes	O
in	O
the	O
lower	O
lumbar	O
spine.	O
Relatively	O
mild	O
degenerative	O
changes	O
in	O
the	O
left	O
hip	B-Hip_fracture
joint,	O
symmetric	O
with	O
the	O
appearance	O
on	O
the	O
right.	O
No	O
evidence	O
of	O
fracture.	B-Hip_fracture
However,	O
if	O
an	O
occult	O
fracture	O
is	O
a	O
serious	O
clinical	O
concern,	O
MRI	O
could	O
be	O
obtained.	O
CT	O
CHEST	O
___:	O
IMPRESSION:	O
1.	O
No	O
acute	O
pulmonary	O
parenchymal	O
findings.	O
2.	O
Moderate	O
emphysema.	O
7	O
mm	O
nodule	O
versus	O
component	O
of	O
subpleural	O
scarring	O
in	O
the	O
right	O
apex,	O
and	O
a	O
additional	O
bilateral	O
pulmonary	O
nodules.	O
In	O
this	O
patient	O
with	O
underlying	O
emphysema,	O
___	O
noncontrast	O
CT	O
of	O
the	O
chest	O
in	O
___	O
months	O
is	O
recommended.	O
3.	O
Ill-defined	O
lesion	O
measuring	O
approximately	O
2.6	O
x	O
3.4	O
x	O
2.4	O
cm	O
in	O
the	O
hepatic	O
dome,	O
which	O
should	O
be	O
further	O
characterized	O
with	O
multiphasic	O
CT	O
or	O
MRI	O
of	O
the	O
liver.	O
4.	O
Diffuse	O
sclerosis	O
of	O
the	O
T9	O
and	O
T10	O
vertebral	O
bodies,	O
also	O
partially	O
involving	O
the	O
posterior	O
elements.	O
Additional	O
sclerotic	O
lesions	O
in	O
other	O
thoracic	O
vertebral	O
bodies,	O
as	O
well	O
as	O
partially	O
imaged	O
in	O
the	O
L1	O
vertebral	O
body.	O
Findings	O
are	O
concerning	O
for	O
blastic	O
metastases.	O
RECOMMENDATION(S):	O
1.	O
Noncontrast	O
CT	O
of	O
the	O
chest	O
in	O
___	O
months.	O
2.	O
Multiphasic	O
CT	O
or	O
MRI	O
of	O
the	O
liver.	O
KUB	O
___:	O
IMPRESSION:	O
Nonspecific,	O
nonobstructive	O
bowel	O
gas	O
pattern.	O
Sclerosis	O
of	O
multiple	O
vertebral	O
bodies	O
and	O
left	O
iliac	O
bone	O
compatible	O
with	O
known	O
metastatic	O
disease.	O
Brief	O
Hospital	O
Course:	O
SUMMARY:	O
=====================	O
Mr.	O
___	O
is	O
a	O
___	O
yo	O
male	O
with	O
PMHx	O
HTN,	O
T2DM,	O
CKD	O
and	O
castrate-resistant	O
metastatic	O
prostate	O
cancer	O
currently	O
being	O
treated	O
with	O
taxotere/prednisone	O
s/p	O
cycle	O
7	O
day	O
1	O
(___)	O
who	O
presents	O
from	O
___	O
facility	O
with	O
left	O
leg	O
pain/numbness	O
and	O
tingling,	O
low-grade	O
fevers	O
and	O
hyperkalemia.	O
He	O
underwent	O
MRI,	O
which	O
demonstrated	O
C5	O
signal	O
abnormality	O
and	O
C3-5	O
edema	O
without	O
enhancement,	O
as	O
well	O
as	O
narrowing	O
and	O
stenosis	O
of	O
the	O
lumbar	O
spine,	O
but	O
after	O
neurosurgery	O
evaluation,	O
there	O
was	O
no	O
concern	O
for	O
acute	O
cord	O
compression	O
and	O
his	O
weakness	O
was	O
felt	O
to	O
be	O
due	O
to	O
peripheral	O
neuropathy	O
with	O
L4	O
nerve	O
compression	O
and	O
subsequent	O
foot	O
drop.	O
He	O
underwent	O
pelvic/hip	I-Hip_fracture
x-ray	O
without	O
acute	O
fracture.	B-Hip_fracture
He	O
remained	O
afebrile,	O
but	O
given	O
neutropenia	O
and	O
fevers	O
to	O
104,	O
he	O
was	O
initially	O
treated	O
with	O
vancomycin	O
and	O
cefepime	O
before	O
transitioning	O
to	O
augmentin	O
to	O
complete	O
a	O
course	O
until	O
___.	O
Given	O
new	O
hemoptysis,	O
there	O
was	O
concern	O
for	O
possible	O
TB	O
in	O
the	O
setting	O
of	O
a	O
number	O
of	O
risk	O
factors,	O
but	O
workup	O
was	O
negative	O
for	O
active	O
TB.	O
Also	O
complicated	O
by	O
SIADH,	O
thus	O
encouraged	O
fluid	O
restriction.	O
He	O
was	O
evaluated	O
by	O
the	O
physical	O
therapists	O
who	O
recommended	O
rehab,	O
and	O
he	O
was	O
discharged	O
to	O
___	O
with	O
oncology	O
and	O
PCP	O
___.	O
TRANSITIONAL	O
ISSUES:	O
====================	O
[]	O
Assess	O
adherence	O
to	O
fluid	O
restriction,	O
re-check	O
sodium	O
in	O
3d	O
given	O
evidence	O
of	O
SIADH.	O
If	O
having	O
worsening	O
hyponatremia	O
or	O
unable	O
to	O
adhere	O
to	O
fluid	O
restriction,	O
consider	O
nephrology	O
evaluation	O
[]	O
Assess	O
Cr	O
&	O
BUN	O
in	O
3d	O
given	O
fluid	O
restriction	O
[]	O
Final	O
results	O
Quant	O
gold	O
needs	O
to	O
be	O
followed	O
up	O
[]	O
Noted	O
to	O
have	O
3.4	O
cm	O
nodule	O
in	O
hepatic	O
dome	O
noted	O
on	O
imaging,	O
will	O
need	O
multiphasic	O
CT	O
or	O
MRI	O
of	O
liver	O
for	O
___	O
[]	O
Patient	O
needs	O
repeat	O
noncontrast	O
CT	O
of	O
the	O
chest	O
in	O
___	O
months.	O
[]	O
As	O
per	O
neurosurgery,	O
patient	O
may	O
benefit	O
from	O
lumbar	O
spine	O
decompression,	O
but	O
this	O
can	O
be	O
done	O
on	O
an	O
elective	O
outpatient	O
basis	O
[]	O
Held	O
pt's	O
glyburide	O
as	O
dose	O
unknown,	O
please	O
determine	O
if	O
this	O
medication	O
is	O
still	O
necessary	O
[]	O
Oncology:	O
-	O
Given	O
extent	O
of	O
metastatic	O
disease,	O
patient	O
may	O
benefit	O
from	O
PET/CT	O
and	O
further	O
prognostication	O
as	O
well	O
as	O
ongoing	O
___	O
discussions	O
-	O
Per	O
radiology	O
read	O
of	O
MRI,	O
patient	O
may	O
benefit	O
from	O
further	O
assessment	O
from	O
high-resolution	O
targeted	O
imaging	O
of	O
the	O
cervical	O
spine	O
#CODE:	O
DNR/DNI,	O
confirmed	O
#CONTACT:	O
___	O
(friend),	O
unknown	O
phone	O
number	O
ACTIVE	O
ISSUES:	O
======================	O
#	O
Prostate	O
Cancer	O
#	O
Osseous	O
Metastases	O
#	O
L	O
leg	O
weakness	O
Pt	O
with	O
hx	O
castrate-resistant	O
metastatic	O
prostate	O
cancer	O
currently	O
being	O
treated	O
with	O
taxotere/prednisone	O
s/p	O
cycle	O
7	O
day	O
1	O
(___).	O
Given	O
left	O
leg	O
symptoms,	O
there	O
was	O
initially	O
concern	O
for	O
cord	O
compression.	O
Exam	O
was	O
notable	O
for	O
decrease	O
dorsiflexion	O
of	O
the	O
left	O
foot,	O
but	O
the	O
remainder	O
of	O
the	O
exam	O
was	O
within	O
normal	O
limits.	O
He	O
underwent	O
MRI	O
of	O
the	O
spine	O
which	O
demonstrated	O
extensive	O
osseous	O
metastatic	O
disease	O
without	O
evident	O
pathologic	O
fracture	O
and	O
retroperitoneal	O
lymphadenopathy.	O
They	O
also	O
noted	O
C5	O
signal	O
abnormality	O
and	O
C3-5	O
edema	O
without	O
enhancement,	O
as	O
well	O
as	O
narrowing/stenosis	O
in	O
lumbar	O
spine.	O
He	O
was	O
evaluated	O
by	O
Spine	O
who	O
recommended	O
no	O
emergent	O
intervention,	O
and	O
this	O
was	O
ultimately	O
felt	O
to	O
be	O
a	O
peripheral	O
process	O
with	O
L4	O
nerve	O
compression	O
and	O
subsequent	O
foot	O
drop.	O
Given	O
hip	B-Hip_fracture
pain,	O
he	O
underwent	O
X-ray,	O
which	O
did	O
not	O
show	O
acute	O
fracture,	B-Hip_fracture
although	O
notable	O
for	O
sclerosis	O
c/w	O
metastases,	O
and	O
mild	O
degenerative	O
changes	O
of	O
the	O
left	O
hip.	O
Heme/onc	O
was	O
consulted	O
and	O
the	O
patient	O
was	O
continued	O
on	O
his	O
home	O
enzalutamide	O
160mg	O
PO	O
daily	O
(after	O
missing	O
3	O
doses	O
due	O
to	O
transportation	O
issue)	O
as	O
well	O
as	O
prednisone	O
10mg	O
PO	O
QAM	O
and	O
5mg	O
PO	O
QPM.	O
He	O
was	O
evaluated	O
by	O
the	O
physical	O
therapists	O
who	O
recommended	O
physical	O
therapy	O
at	O
___,	O
but	O
he	O
may	O
also	O
benefit	O
from	O
directed	O
therapy	O
of	O
his	O
now	O
known	O
foot	O
drop.	O
He	O
will	O
___	O
with	O
his	O
outpatient	O
oncologist,	O
Dr.	O
___	O
he	O
would	O
benefit	O
from	O
an	O
ongoing	O
___	O
discussion	O
given	O
the	O
extent	O
of	O
his	O
disease.	O
He	O
also	O
would	O
benefit	O
from	O
further	O
assessment	O
of	O
his	O
cervical	O
spine	O
disease	O
with	O
high-resolution	O
targeted	O
imaging	O
as	O
well	O
imaging	O
his	O
3.4	O
cm	O
nodule	O
in	O
hepatic	O
dome	O
noted	O
on	O
imaging	O
with	O
multiphasic	O
CT	O
or	O
MRI	O
of	O
liver.	O
#	O
Hemoptysis	O
#	O
Neutropenia	O
Pt	O
currently	O
undergoing	O
chemotherapy	O
with	O
WBC	O
2.4	O
and	O
ANC	O
1030	O
that	O
nadired	O
during	O
this	O
hopstilaizaiton	O
at	O
730.	O
He	O
Reports	O
a	O
temp	O
104	O
last	O
week,	O
however	O
has	O
had	O
low-grade	O
temps	O
more	O
recently	O
and	O
was	O
found	O
to	O
have	O
Tmax	O
99	O
here.	O
Given	O
productive	O
cough	O
and	O
CXR	O
w/	O
hyperdensity	O
overlying	O
the	O
vertebrae	O
of	O
the	O
lower	O
thoracic	O
spine,	O
concernign	O
for	O
metastases	O
versus	O
pneumonia,	B-Lower_respiratory_tract_infection
he	O
was	O
initially	O
treated	O
with	O
vancomycin/cefepime	O
for	O
concern	O
for	O
neutorpenic	O
fever	O
before	O
transitioning	O
to	O
augmentin	O
after	O
remaining	O
afebrile/hemodynamically	O
stable	O
to	O
complete	O
a	O
course	O
until	O
___.	O
During	O
the	O
hospitalization,	O
he	O
developed	O
multiple	O
episodes	O
of	O
hemoptysis	O
as	O
well	O
as	O
night	O
sweats	O
and	O
given	O
his	O
number	O
of	O
risk	O
factors	O
(incarcerated,	O
?positive	O
PPD,	O
immunosuppresion),	O
he	O
was	O
isolated	O
and	O
underwent	O
expectorated	O
sputum	O
for	O
AFB	O
+	O
MTB	O
direct	O
amp,	O
which	O
was	O
unrevealing.	O
The	O
Quant-Gold	O
was	O
drawn,	O
but	O
is	O
still	O
pending.	O
He	O
had	O
CT	O
contrast	O
of	O
the	O
chest	O
that	O
demonstrated	O
no	O
acute	O
pulmonary	O
parenchymal	O
findings	O
with	O
moderate	O
emphysema	O
and	O
was	O
noted	O
to	O
have	O
a	O
7	O
mm	O
nodule	O
versus	O
component	O
of	O
subpleural	O
scarring	O
in	O
the	O
right	O
apex,	O
and	O
additional	O
bilateral	O
pulmonary	O
nodules.	O
He	O
should	O
have	O
repeat	O
CT	O
imaging	O
of	O
the	O
chest	O
in	O
___	O
months.	O
#	O
SIADH	O
Intermittent	O
throughout	O
hospitalization.	O
Hyponatremia	O
is	O
known	O
SE	O
of	O
pt's	O
enzalutamide.	O
Improved	O
with	O
fluid	O
restriction.	O
Should	O
continue	O
1.2L	O
fluid	O
restriction	O
upon	O
discharge.	O
#	O
Hyperkalemia,	O
resolved:	O
Pt	O
with	O
reports	O
of	O
hyperK	O
at	O
___,	O
treated	O
with	O
Ca,	O
insulin/dextrose,	O
albuterol.	O
His	O
potassium	O
remained	O
wnl	O
at	O
___,	O
and	O
no	O
further	O
intervention	O
was	O
pursued.	O
#	O
Anemia:	O
Hgb	O
was	O
between	O
7.9-8.3	O
this	O
admission,	O
which	O
appears	O
to	O
be	O
close	O
to	O
baseline	O
based	O
upon	O
review	O
of	O
records.	O
This	O
has	O
been	O
worked	O
up	O
as	O
an	O
outpatient	O
and	O
he	O
is	O
on	O
home	O
ferrous	O
sulfate	O
325	O
BID,	O
but	O
there	O
is	O
likely	O
a	O
component	O
of	O
anemia	O
of	O
chronic	O
disease.	O
Held	O
iron	O
while	O
inpatient	O
d/t	O
concern	O
for	O
constipation,	B-Constipation
okay	O
to	O
resume	O
upon	O
discharge.	O
His	O
home	O
naproxen	O
was	O
initially	O
held	O
in	O
the	O
setting	O
of	O
concern	O
for	O
bleeding,	O
but	O
it	O
was	O
continued	O
on	O
discharge.	O
#	O
Constipation:	B-Constipation
pt	O
had	O
several	O
days	O
of	O
constipation	B-Constipation
without	O
abdominal	O
pain.	O
KUB	O
was	O
obtained	O
without	O
signs	O
of	O
obstruction,	O
and	O
his	O
bowel	O
regimen	O
was	O
increased	O
aggressively	O
with	O
eventual	O
bowel	O
movement.	O
Will	O
be	O
discharged	O
on	O
standing	O
PEG	O
BID	O
+	O
senna	O
BID	O
+	O
Bisacodyl	O
PR	O
QHS	O
CHRONIC	O
ISSUES:	O
===============	O
#	O
HTN:	O
cont	O
isosorbide	O
dinitrate	O
20	O
mg	O
PO	O
TID,	O
diltiazem	O
ER	O
360	O
mg	O
PO	O
qd,	O
Furosemide	O
20	O
mg	O
PO	O
qd	O
#	O
T2DM:	O
metformin	O
and	O
glyburide	O
was	O
held	O
while	O
inpatient.	O
Metformin	O
was	O
resumed	O
on	O
discharge.	O
As	O
the	O
patient's	O
home	O
glyburide	O
dose	O
was	O
unclear,	O
this	O
medication	O
was	O
held	O
on	O
discharge	O
pending	O
PCP	O
___.	O
#	O
GERD:	O
cont	O
home	O
pantoprazole	O
40mg	O
qd	O
#	O
Eye	O
drops:	O
continue	O
home	O
birmonidine,	O
bimatoprost,	O
and	O
dorzolamide	O
#	O
Allergies:	O
continue	O
home	O
cetirizine	O
10mg	O
PO	O
QHS	O
PRN	O
#	O
Vit	O
D	O
deficiency:	O
continue	O
vitamin	O
D	O
2000U	O
daily	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Isosorbide	O
Dinitrate	O
20	O
mg	O
PO	O
TID	O
2.	O
Pantoprazole	O
40	O
mg	O
PO	O
Q24H	O
3.	O
Albuterol	O
Inhaler	O
2	O
PUFF	O
IH	O
Q4H:PRN	O
sob,	O
wheezing	O
4.	O
Diltiazem	O
Extended-Release	O
360	O
mg	O
PO	O
DAILY	O
5.	O
Methocarbamol	O
500	O
mg	O
PO	O
BID	O
6.	O
Furosemide	O
20	O
mg	O
PO	O
DAILY	O
7.	O
PredniSONE	O
10	O
mg	O
PO	O
QAM	O
8.	O
MetFORMIN	O
(Glucophage)	O
850	O
mg	O
PO	O
BID	O
9.	O
GlyBURIDE	O
Dose	O
is	O
Unknown	O
PO	O
Frequency	O
is	O
Unknown	O
10.	O
PredniSONE	O
5	O
mg	O
PO	O
QPM	O
11.	O
enzalutamide	O
160	O
mg	O
oral	O
DAILY	O
12.	O
Naproxen	O
500	O
mg	O
PO	O
Q12H:PRN	O
Pain	O
-	O
Moderate	O
13.	O
Acetaminophen	O
650	O
mg	O
PO	O
Q6H:PRN	O
Pain	O
-	O
Mild/Fever	O
14.	O
GuaiFENesin	O
ER	O
600	O
mg	O
PO	O
BID:PRN	O
congestion	O
15.	O
Dorzolamide	O
2%	O
Ophth.	O
Soln.	O
1	O
DROP	O
BOTH	O
EYES	O
TID	O
16.	O
Brimonidine	O
Tartrate	O
0.15%	O
Ophth.	O
1	O
DROP	O
BOTH	O
EYES	O
Q8H	O
17.	O
Cetirizine	O
10	O
mg	O
PO	O
QHS:PRN	O
allergy,	O
insomnia	O
18.	O
Vitamin	O
D	O
___	O
UNIT	O
PO	O
DAILY	O
19.	O
Lactulose	O
15	O
mL	O
PO	O
BID:PRN	O
Constipation	B-Constipation
20.	O
Ferrous	O
Sulfate	O
325	O
mg	O
PO	O
BID	O
21.	O
Bimatoprost	O
0.03%	O
Ophth	O
(*NF*)	O
1	O
drop	O
Other	O
QHS	O
Discharge	O
Medications:	O
1.	O
Aluminum-Magnesium	O
Hydrox.-Simethicone	O
___	O
mL	O
PO	O
QHS:PRN	O
indigestion	O
2.	O
Amoxicillin-Clavulanic	O
Acid	O
___	O
mg	O
PO	O
Q12H	O
Duration:	O
6	O
Days	O
3.	O
Bisacodyl	O
10	O
mg	O
PR	O
QHS:PRN	O
Constipation	B-Constipation
-	O
Second	O
Line	O
4.	O
Lidocaine	O
5%	O
Patch	O
1	O
PTCH	O
TD	O
QAM	O
5.	O
Ondansetron	O
4	O
mg	O
PO	O
Q8H:PRN	O
Nausea/Vomiting	O
-	O
First	O
Line	O
6.	O
OxyCODONE	O
(Immediate	O
Release)	O
5	O
mg	O
PO	O
Q8H:PRN	O
Pain	O
-	O
Moderate	O
RX	O
*oxycodone	O
5	O
mg	O
1	O
tablet(s)	O
by	O
mouth	O
every	O
eight	O
(8)	O
hours	O
Disp	O
#*9	O
Tablet	O
Refills:*0	O
7.	O
Polyethylene	O
Glycol	O
17	O
g	O
PO	O
BID	O
8.	O
Senna	O
8.6	O
mg	O
PO	O
BID	O
9.	O
Acetaminophen	O
650	O
mg	O
PO	O
Q6H:PRN	O
Pain	O
-	O
Mild/Fever	O
10.	O
Albuterol	O
Inhaler	O
2	O
PUFF	O
IH	O
Q4H:PRN	O
sob,	O
wheezing	O
11.	O
Bimatoprost	O
0.03%	O
Ophth	O
(*NF*)	O
1	O
drop	O
Other	O
QHS	O
12.	O
Brimonidine	O
Tartrate	O
0.15%	O
Ophth.	O
1	O
DROP	O
BOTH	O
EYES	O
Q8H	O
13.	O
Cetirizine	O
10	O
mg	O
PO	O
QHS:PRN	O
allergy,	O
insomnia	O
14.	O
Diltiazem	O
Extended-Release	O
360	O
mg	O
PO	O
DAILY	O
15.	O
Dorzolamide	O
2%	O
Ophth.	O
Soln.	O
1	O
DROP	O
BOTH	O
EYES	O
TID	O
16.	O
enzalutamide	O
160	O
mg	O
oral	O
DAILY	O
17.	O
Ferrous	O
Sulfate	O
325	O
mg	O
PO	O
BID	O
18.	O
Furosemide	O
20	O
mg	O
PO	O
DAILY	O
19.	O
GuaiFENesin	O
ER	O
600	O
mg	O
PO	O
BID:PRN	O
congestion	O
20.	O
Isosorbide	O
Dinitrate	O
20	O
mg	O
PO	O
TID	O
21.	O
Lactulose	O
15	O
mL	O
PO	O
BID:PRN	O
Constipation	B-Constipation
22.	O
MetFORMIN	O
(Glucophage)	O
850	O
mg	O
PO	O
BID	O
23.	O
Methocarbamol	O
500	O
mg	O
PO	O
BID	O
24.	O
Pantoprazole	O
40	O
mg	O
PO	O
Q24H	O
25.	O
PredniSONE	O
10	O
mg	O
PO	O
QAM	O
26.	O
PredniSONE	O
5	O
mg	O
PO	O
QPM	O
27.	O
Vitamin	O
D	O
___	O
UNIT	O
PO	O
DAILY	O
28.	O
HELD-	O
GlyBURIDE	O
Dose	O
is	O
Unknown	O
PO	O
Frequency	O
is	O
Unknown	O
This	O
medication	O
was	O
held.	O
Do	O
not	O
restart	O
GlyBURIDE	O
until	O
discussing	O
with	O
your	O
primary	O
care	O
provider.	O
Discharge	O
Disposition:	O
Extended	O
Care	O
Facility:	O
___	O
Discharge	O
Diagnosis:	O
PRIMARY:	O
Lumbar	O
Radiculopathy	O
SECONDARY:	O
Prostate	O
cancer	O
with	O
osseous	O
metastases	O
Hypertension	O
SIADH	O
Anemia	O
Constipation	B-Constipation
Hemoptysis	O
Type	O
2	O
Diabetes	O
Mellitus	O
Discharge	O
Condition:	O
Mental	B-Delirium
Status:	B-Delirium
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Mobile_with_assistance
-	B-Mobile_with_assistance
requires	B-Mobile_with_assistance
assistance	B-Mobile_with_assistance
or	O
aid	B-Mobile_with_aid
(walker	O
or	O
cane).	O
Discharge	O
Instructions:	O
Dear	O
Mr.	O
___,	O
It	O
was	O
a	O
pleasure	O
taking	O
part	O
in	O
your	O
care	O
here	O
at	O
___!	O
Why	O
was	O
I	O
admitted	O
to	O
the	O
hospital?	O
-	O
You	O
were	O
admitted	O
for	O
left	O
leg	O
weakness	O
What	O
was	O
done	O
for	O
me	O
while	O
I	O
was	O
in	O
the	O
hospital?	O
-	O
You	O
had	O
an	O
MRI	O
that	O
showed	O
evidence	O
of	O
cancer	O
metastases	O
to	O
the	O
spine	O
and	O
severe	O
degenerative	O
changes,	O
without	O
clear	O
evidence	O
of	O
compression	O
of	O
the	O
spinal	O
cord	O
-	O
You	O
were	O
evaluate	O
by	O
the	O
neurosurgeons	O
who	O
did	O
not	O
feel	O
as	O
if	O
there	O
was	O
an	O
indication	O
for	O
surgery	O
at	O
this	O
time	O
-	O
You	O
had	O
a	O
hip	B-Hip_fracture
x-ray,	O
which	O
did	O
not	O
show	O
a	O
fracture	B-Hip_fracture
-	O
We	O
gave	O
you	O
pain	O
medications	O
to	O
treat	O
your	O
leg	O
pain	O
-	O
You	O
were	O
treated	O
with	O
antibiotics	O
for	O
concern	O
for	O
an	O
infection	O
-	O
There	O
was	O
concern	O
for	O
possible	O
TB	O
because	O
of	O
coughing	O
up	O
blood,	O
but	O
we	O
did	O
the	O
testing	O
to	O
show	O
that	O
you	O
do	O
not	O
have	O
an	O
active	O
TB	O
invection	O
-	O
You	O
were	O
treated	O
with	O
a	O
bowel	O
regimen	O
to	O
help	O
you	O
have	O
a	O
bowel	O
movement	O
-	O
We	O
encouraged	O
you	O
to	O
limit	O
the	O
amount	O
of	O
fluids	O
you	O
drink	O
because	O
of	O
your	O
electrolyte	O
levels	O
(low	O
sodium).	O
You	O
should	O
not	O
drink	O
more	O
than	O
1.2	O
liters	O
of	O
water	O
per	O
day.	O
What	O
should	O
I	O
do	O
when	O
I	O
leave	O
the	O
hospital?	O
-	O
Continue	O
to	O
take	O
all	O
of	O
your	O
medications	O
as	O
prescribed	O
-	O
Keep	O
all	O
of	O
your	O
scheduled	O
appointemnts	O
Sincerely,	O
Your	O
___	O
Care	O
Team	O
Followup	O
Instructions:	O
___	O

